Buys | $0 | 0 | 0 |
Sells | $771,602 | 5 | 100 |
Loomis David K | Chief Accounting Officer | 0 | $0 | 2 | $26,731 | $-26,731 |
Cacace Angela M | Chief Scientific Officer | 0 | $0 | 1 | $70,238 | $-70,238 |
Taylor Ian | President, R&D | 0 | $0 | 1 | $150,752 | $-150,752 |
Houston John G | President and CEO | 0 | $0 | 1 | $523,881 | $-523,881 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of …
Over the last 12 months, insiders at Arvinas, Inc. have bought $0 and sold $771,602 worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $21.11M and sold $29.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 285,714 shares for transaction amount of $20M was made by Ratcliffe Liam (director) on 2020‑12‑18.
2025-02-24 | Sale | Houston John G | President and CEO | 31,338 0.0429% | $16.72 | $523,881 | +3.45% | |
2025-02-24 | Sale | Taylor Ian | President, R&D | 9,020 0.0123% | $16.71 | $150,752 | +3.45% | |
2025-02-24 | Sale | Cacace Angela M | Chief Scientific Officer | 4,207 0.0057% | $16.70 | $70,238 | +3.45% | |
2025-02-24 | Sale | Loomis David K | Chief Accounting Officer | 1,214 0.0017% | $16.75 | $20,335 | +3.45% | |
2024-11-07 | Sale | Loomis David K | Chief Accounting Officer | 231 0.0003% | $27.69 | $6,396 | -32.70% | |
2024-02-23 | Sale | Houston John G | President and CEO | 5,196 0.0095% | $47.05 | $244,472 | -44.89% | |
2024-02-23 | Sale | Cassidy Sean A | Chief Financial Officer | 1,702 0.0031% | $47.05 | $80,079 | -44.89% | |
2024-02-23 | Sale | Taylor Ian | Chief Scientific Officer | 1,701 0.0031% | $47.05 | $80,032 | -44.89% | |
2024-02-23 | Sale | Peck Ronald | Chief Medical Officer | 1,699 0.0031% | $47.05 | $79,938 | -44.89% | |
2023-11-08 | Sale | Loomis David K | Chief Accounting Officer | 229 0.0004% | $17.05 | $3,904 | +80.56% | |
2023-08-11 | Sale | Peck Ronald | Chief Medical Officer | 1,324 0.0024% | $24.39 | $32,289 | +20.32% | |
2023-03-01 | Sale | Houston John G | President and CEO | 5,878 0.0107% | $29.53 | $173,577 | -14.30% | |
2023-03-01 | Sale | Cassidy Sean A | Chief Financial Officer | 1,745 0.0032% | $29.53 | $51,530 | -14.30% | |
2023-03-01 | Sale | Taylor Ian | Chief Scientific Officer | 1,051 0.0019% | $29.53 | $31,036 | -14.30% | |
2022-08-12 | Sale | Peck Ronald | Chief Medical Officer | 1,258 0.0024% | $54.84 | $68,994 | -40.82% | |
2022-04-14 | Sale | Morrison Briggs | 10,754 0.0202% | $67.03 | $720,888 | -36.79% | ||
2022-03-11 | Sale | Cassidy Sean A | Chief Financial Officer | 15,000 0.029% | $70.00 | $1.05M | -36.08% | |
2022-03-04 | Sale | Houston John G | President and CEO | 6,024 0.0113% | $63.94 | $385,175 | -31.76% | |
2022-03-04 | Sale | Cassidy Sean A | Chief Financial Officer | 1,593 0.003% | $63.94 | $101,856 | -31.76% | |
2022-03-04 | Sale | Taylor Ian | Chief Scientific Officer | 869 0.0016% | $63.94 | $55,564 | -31.76% |
Houston John G | President and CEO | 1157480 1.6831% | $9.76M | 1 | 11 | +24.92% |
Taylor Ian | President, R&D | 159121 0.2314% | $1.34M | 1 | 13 | +66.46% |
RA CAPITAL MANAGEMENT, LLC | 3138412 4.5635% | $26.46M | 1 | 0 | +24.92% | |
SHANNON TIMOTHY M | director | 1653128 2.4038% | $13.94M | 5 | 11 | +45.5% |
Flynn James E | 10 percent owner | 411245 0.598% | $3.47M | 1 | 0 | +24.92% |
$3,596,906 | 112 | 13.42% | $635.29M | |
$36,510,315 | 95 | 8.95% | $609.56M | |
$587,109,125 | 90 | 3.17% | $527.16M | |
$678,065,999 | 37 | -13.32% | $603.22M | |
$94,912,877 | 34 | -7.15% | $626.42M |
Increased Positions | 109 | +50.23% | 12M | +16.16% |
Decreased Positions | 89 | -41.01% | 10M | -13.61% |
New Positions | 28 | New | 4M | New |
Sold Out Positions | 36 | Sold Out | 6M | Sold Out |
Total Postitions | 237 | +9.22% | 74M | +2.55% |
Vanguard Group Inc | $125,007.00 | 10.24% | 7.06M | +56,561 | +0.81% | 2024-12-31 |
Ecor1 Capital, Llc | $119,059.00 | 9.75% | 6.73M | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $116,221.00 | 9.52% | 6.57M | +70,059 | +1.08% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $72,623.00 | 5.95% | 4.1M | +249,295 | +6.47% | 2024-12-31 |
Rtw Investments, Lp | $59,017.00 | 4.83% | 3.33M | +551,979 | +19.84% | 2024-12-31 |
Citadel Advisors Llc | $54,386.00 | 4.45% | 3.07M | +365,117 | +13.48% | 2024-12-31 |
Bellevue Group Ag | $42,296.00 | 3.46% | 2.39M | +3,000 | +0.13% | 2024-12-31 |
T. Rowe Price Investment Management, Inc. | $39,086.00 | 3.2% | 2.21M | +2M | New | 2024-12-31 |
Ubs Group Ag | $36,081.00 | 2.95% | 2.04M | +2M | +332.26% | 2024-12-31 |
Jpmorgan Chase & Co | $32,870.00 | 2.69% | 1.86M | -472,225 | -20.27% | 2024-12-31 |